Cultivated Globally
SPECIALIZING IN THE ACQUISITION AND OPERATION OF INTERNATIONAL CANNABIS ASSETS
CSE:WRLD.U FWB:8K51 OTC:WLDCF About ICC
ICC International Cannabis, through its subsidiaries, has operating assets and is developing a world class platform for cultivation, extraction, formulation and distribution across the globe in the United Kingdom, Denmark, Poland, Switzerland, Germany, Macedonia, Bulgaria, Greece, Italy, Portugal, Malta, Colombia, Argentina, Australia, South Africa and Lesotho.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF About ICC - Europe
Denmark Portugal Germany Licences for cannabis cultivation Cultivation, extraction, formulation and Cannabis import licence, EU-GMP and manufacturing export of CBD products certified packaging and distribution center, 165 hectares of CBD cultivation
Poland Greece Italy Licences for the extraction and Interest in CBD production licences with Candidate for one of seven medical manufacturing of CBD products conditional pre-approval for a medical Cannabis cultivation licences, CBD cannabis licence cultivation and distribution
Macedonia Bulgaria United Kingdom Licences for medical cannabis Licences for medical cannabis One of three companies to cultivation, extraction, formulation and cultivation, extraction, formulation and successfully import medical export export cannabis
Switzerland Malta Cannabis cultivation and Import/export and processing for extraction finished-dose medical cannabis
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF About ICC
South America Africa Oceania
Colombia Lesotho Australia Licences to cultivate, produce, Licences to cultivate, produce, Late stage medical cannabis distribute, store, and export distribute, store, and export cultivation applicant, coupled cannabis and cannabis derivatives cannabis and cannabis products with a Northern Territory sponsorship
Argentina 820 hectares of potential outdoor cultivation
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF About ICC
EU-GMP MEDICAL CANNABIS IMPORT AGREEMENT OVER A FOR CULTIVATION, SPANNING 35,000 THREE YEAR TERM WITH 19 FOUR CONTINENTS. LICENCES KG WAYLAND GROUP
OF CBD ISOLATE 50,000 OF CBD ISOLATE IN 2019 2,400 PRODUCED IN 2018 KG KG
OVER OF FORECASTED DRIED CANNABIS CANNABIS STRAINS 740,000 PRODUCTION FROM OUTDOOR 2,700 KG CANNABIS CULTIVATIONV
39,100 REPRESENTING 110 CLIENTS IN 16 COUNTRIES PHARMACIES
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF Denmark BuyWell Care Ecosystem
On January 17, 2019, International Cannabis announced its intentions to launch the first European Guaranteed Issue Medical Cannabis Coverage.
International Cannabis, Evergreen Pacific and Cannops will collaborate to introduce transformative extended healthcare coverages, including cannabinoid therapeutic coverage, to the European marketplace.
European Union: The BuyWell Care Ecosystem: The BuyWell Care’s patient centric • Over 500 million potential • First of its kind transformative coverage platform is aimed at addressing the consumers; for cannabinoid therapeutic treatment market needs of the European • Over 1.6 million health care via the BuyWell Care platform; alternative health space, while meeting practitioners; and, • Online medical cannabis coverages the following objectives: • Annual healthcare expenditures utilizing a proprietary pricing • Make alternative health care easy and of $1.79 trillion in 2018. methodology; affordable; • Streamlined access to top-tier • Ensure the patient can pay when the alternative healthcare services; service or product is provided; • CBD Health and Wellness ecommerce • Support the patient with educational marketplace; and, resources, clinical services, and post- • Educational platform for medical treatment follow-up; and, practitioners. • Guide the patient along multiple potential treatment pathways.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF ICC CBD Brand Portfolio
ICC International Cannabis Corp. has entered into a licensing agreement with Authentic Brands Group (ABG), to market and distribute cannabidiol-derived health and wellness products throughout Europe under the Marilyn Monroe, Elvis Presley, Greg Norman, Tretorn, Aeropostale, Thalia (Spain only) and Frederick’s of Hollywood brands. ICC will leverage these widely recognized and trusted powerhouse brands that are already prominently featured on thousands House of Brands of store shelves across Europe. This will enhance ICC’s opportunity to capture significant share in the following rapidly growing lifestyle and wellness categories:
• Active/outdoor: Greg Norman, Marilyn Monroe and Tretorn; • Beauty and cosmetics: Marilyn Monroe, Elvis Presley, Thalia and Frederick’s of Hollywood; • Wellness and supplements: Greg Norman, Thalia and Marilyn Monroe; • Foot care: Tretorn and Greg Norman; • Health and wellness: Greg Norman, Aeropostale, Thalia and Tretorn; • Lifestyle: Elvis Presley, Aeropostale, Marilyn Monroe and Frederick’s of Hollywood; • Pet: Elvis Presley, Greg Norman, Marilyn Monroe and Tretorn; • Remedy: Greg Norman, Aeropostale and Tretorn; and, • Sexual wellness: Elvis Presley, Frederick’s of Hollywood and Marilyn Monroe.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF CULTIVATE, PRODUCE, CANNABIS AND HEMP IN GERMANY MARICANN GMBH & MARIPLANT GMBH
Ø Population: 82.2m GERMANY Ø Health Care Expenditures: 425.8b Euro
Location: Germany International Cannabis holds a German medical Cannabis import licence and has secured a three-year supply contract to import 35,000 kg of medical cannabis over three years. Highlights International Cannabis’ European nutraceutical subsidiary, harvested over 120,000 kg of dry hemp flowers for processing into • Production of 2,400 kg of CBD resin. This inaugural harvest utilized new proprietary harvesting and drying systems, designed to optimize yield from industrial isolate in 2018. hemp. At a 12,000 Euro per kg with an estimated wholesale value of $21,866,000 CAD. • Expanding to 500 hectares of cultivation in 2019, and 15,00 The Company also an applicant for an indoor medical THC cultivation license, as well as a 164-hetare outdoor industrial hemp kg of CBD isolate. cultivation operation. In August 2018, International Cannabis commenced its first harvest of industrial hemp. • Contract production manufacturing of CBD In September 2018, International Cannabis commenced sale of its CBD capsules, distributed through pharmacies in Germany. products, including existing softgel product, and tinctures.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF CULTIVATE, PRODUCE, CANNABIS AND HEMP IN GERMANY EBERSBACH FACILITY
• Located near Dresden, Germany • 820,000 square feet of potential clean room cultivation • EU-GMP certificate • EU-GMP – narcotics import • EU-GMP – narcotics wholesale • Inventory of dried hemp and resin • Annual output and production of a minimum of 2,400 kg of CBD isolate
The Company’s current German operations are designed to import product from other International Cannabis sites. The Ebersbach facility is an integral part of that operation; product will be stored and packaged in Ebersbach in an approved EU-GMP certified packaging and distribution center.
The German patient population is growing exponentially- over 79,000 patients, up from ~800 in 2017.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF LICENSES FOR CANNABIS CULTIVATION AND MANUFACTURING, MANAGEMENT, AGRICULTURAL TECHNOLOGIES DANAVIAN CANNABIS LTD.
Ø Population: 5.7m DENMARK Ø Health Care Expenditures: 22.6b Euro Ø Estimated Cannabis Requirement 2018: 135,000 grams
Location: Moeldrup, Denmark Danavian controls licenses for cannabis cultivation and manufacturing in the Kingdom of Denmark. Danavian holds claim to premier European cannabis assets; domiciled in a Highlights jurisdiction with a highly skilled agriculture and manufacturing workforce. Davavian also boasts various industry relationships that will complement future development potential throughout Scandinavia. • 49,000 square foot, fully automated greenhouse • Denmark is positioned in immediate proximity to Germany, allowing for The Company has increased its Danish landholdings and now controls a 100-acre property direct imports of CBD products, as well as medical Cannabis flower. located in the municipality of Moeldrup. Initial development work, as well as the adaptation • Finished cannabis and cannabis derivatives produced by Danavian will of infrastructure for the property, is scheduled to commence in January of 2019. be sold through Denmark’s retail pharmacy network. Stage A of International Cannabis's Danish medical cannabis facility will include a 49,600- square-foot cultivation unit, as well as a production and processing structure. All structures scheduled for construction have been designed to comply with EU-GMP standards.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF HEMP PROCESSING AND EXTRACTION FACILITIES PRODUCING CBD DERIVED PRODUCTS POLANNABIS HOLDINGS
Ø Population: 38.5m POLAND Ø Health Care Expenditures: 33.04b Euro
Location: Poland Polannabis, through its subsidiary controls a Polish hemp processing and extraction licence. The licence permits the extraction and manufacturing of CBD-derived products from hemp. Highlights Polannabis has access to over 850 acres of premium hemp crops; estimated to produce up • Operations are currently producing CBD distillate, isolate, bulk to 6,800 tons of material for CBD extraction. Polannabis boasts an existing extraction and oils, topicals and tincture manufacturing facility, equipped with a proprietary Hydrocarbon extraction technologies. • Highly experienced roster of engineering, scientific, logistics, marketing and sales personnel Polannabis has secured a monthly off-take agreement for 100 kilos of 99.9% CBD isolate. • Existing sales agreements in various EU member countries The off-take agreement will be initiated immediately upon the completion of its planned capacity and processing expansion.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF MEDICAL CANNABIS IMPORTATION INTO THE UNITED KINGDOM THEROS PHARMA LTD.
Ø Population: 65.6m UNITED KINGDOM Ø Healthcare Expenditures: 221.7b Euro
Location: United Kingdom Theros Pharma Ltd., an early-stage company that has successfully imported cannabis to the U.K. for patients with a prescription for medical cannabis. Highlights Recent U.K. legislation allows for the prescription of cannabis from a medical specialist via a regular pharmacy model, • Successfully imported cannabis coupled with National Health Service insurance coverage for medical cannabis to ensure patient outcomes. to the U.K. for patients with a prescription for medical cannabis. • Dr. Michael Bares, established neurologist and Cannabis physician, helped to legalize cannabis for medical purposes in the UK.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF PROCURE & DISTRIBUTE MARATHON GLOBAL INC.
Location: Europe Marathon Global has an exclusive agreement with Cosmos Holdings, a European based pharmaceutical distributor, to procure and distribute medical cannabis products and all cannabis derivatives for clients of Cosmos in approved countries within its Highlights distribution network of 110 clients, representing approximately 36,130 pharmacies.
• European based pharmaceutical Cosmos has a trans-European network of over 160 clients and vendors, which expands to 16 countries, including: Germany, distribution United Kingdom, Ireland, Denmark, Italy, France, Lebanon, Macedonia, Sweden, Poland, the Netherlands and Greece. • Network of 110 clients • 36,130 pharmacies in 16 countries On November 7th, 2018 International Cannabis announced it has received an inaugural purchase order from Cosmos for • European network of over 160 10,000mL of THC Cannabis oil, 5,000g of dried Cannabis flower and 5,000mL of CBD oil.. International Cannabis expects to clients and vendors receive subsequent Purchase Orders throughout 2019. The Company has also commenced a dedicated European sales campaign, with the objective of augmenting impromptu, inbound demand.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF CULTIVATION, PROCESSING AND IMPORT/EXPORT OF HEMP-DERIVED PRODUCTS ENIGMA UNIPESSOAL LDA
Ø Population: 10.31m PORTUGAL Ø Healthcare Expenditures: 17.3b Euro
Location: Portugal Enigma controls one of the first hemp licenses to be issued in Portugal, which permits the cultivation, processing and import/export of hemp-derived products. Enigma successfully harvested and extracted its first hemp crop in 2015, and has Highlights become a notable importer of proprietary hemp seeds.
This licence authorizes International Cannabis to cultivate hemp on 400 acres of fertile agricultural land located in the Castelo • Controls one of the first hemp Branco region of Portugal. licenses to be issued in Portugal • Notable importer of proprietary Engima is progressing towards a full spectrum cannabis license in Portugal, which it is hopeful to achieve before the end of Q1 hemp seeds 2019. • 400 acres of agricultural in the Castelo Branco region
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF PRODUCE, IMPORT CANNABIS IN SWITZERLAND BBI & HAXXON AG
Ø Population: 8.4m Ø Healthcare Expenditures: 54.3b Euro SWITZERLAND Ø Annual Cannabis and Hemp Product Sales 87.8m Euro Ø Estimated Cannabis Requirement 2018: 160,000 grams
Location: Switzerland BBI Partnership • On track to become the first Commercial Production THC License holder in Switzerland Highlights • BBI, medical plant producer based in Thurgau Switzerland. Held two previous research THC licenses • 10 hectare property in Thurgau, near Konstanz. • International Cannabis is • Production of Medical cannabis for the Swiss Market, under Swiss Medic. currently producing from a • Proprietary genetics, developed for outdoor cultivation in South America sites. 60,000 square foot facility in • Only import of THC distillate from Canada to Switzerland to date from secured suppliers Regensdorf, Switzerland, just • License expected in Q2 2019, application process near completion after 18 months. outside of Zurich • Pilot project in Lichtenstein with Hilti • Plans to expand current facility and increase production by a Haxxon Operation factor of 6 • 2019 ~2000 kg - $4M revenue. • $4.2 MM in capex spend to increase capacity to 14,000 kg • Gross margin greater than 50%
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF CANNABIS & HEMP PRODUCTION, CULTIVATION, MANUFACTURING & EXPORT BALKAN CANNABIS CORP.
MACEDONIA Ø Population: 2.074m BULGARIA Ø Population: 7.102m
Location: Macedonia & Bulgaria Balkan Cannabis aims to be the first mover within the Eastern European medical Cannabis and hemp theatre.
Highlights Macedonia Balkan Cannabis has been granted an exclusive agreement with an existing licenced facility, which permits the cultivation, • Exclusive agreement in manufacturing and export of medical Cannabis. The Licenced Facility is located on a 30-hectare land parcel in Valandovo, Macedonia which permits the Macedonia. cultivation, manufacturing and export of medical Cannabis Balkan Cannabis’ Macedonian subsidiary has also been awarded the only Macedonia extraction licence to date and is in the • Awarded the only Macedonia process of building out the country’s first dedicated industrial extraction facility. Once operational, the extraction facility will extraction licence to date essentially control the domestic Macedonian extraction market, making Balkan Cannabis the most dominant player in the region. • Licences in Bulgaria for the production, manufacturing and Bulgaria export of both hemp and medical Balkan Cannabis holds a 50% interest in a Bulgarian subsidiary, which controls licences for the production, manufacturing and cannabis export of both hemp and medical Cannabis. Balkan Cannabis controls a 15,000-hectare land parcel, with a two-year option to acquire an additional 15,000 hectares.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF Why is ICC focusing on CBD in Europe?
A large undeveloped emerging market
Unlike Canada in most European market Available European countries CBD estimated to be is available as an over the 66.8 bil C$66.8 billion by over the counter product stocked By 2020 2020 counter in your local pharmacy and available online
Estimated ST Favourable European 1 governments were 5 to 1 current product demand out first early one of the worlds first product demand strips supply adapters of CBD early adapters of CBD out strips supply 5 to 1
intlcannabiscorp.com
Sources: Marijuana Business Daily, Canaccord Genuity estimate CSE:WRLD.U FWB:8K51 OTC:WLDCF Why Are Our Profits So High? Branding is expensive. Retail is expensive. Bulk sales are efficient.
1 LABEL 50,000 LABELS 1 CONTAINER 50,000 CONTAINERS 1 BOX 50,000 BOXES 1 DELIVERY 50,000 DELIVERIES 1 CLIENT 50,000 PROBLEMS (and we only have 1)
= =
*20ml tinctures at 10% CBD
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF Denmark HEMP CULTIVATION, MANUFACTURING, DISTRIBUTION & EXPORT EU CANNABIS CORP.
Ø Population: 10.77m GREECE Ø Heath Care Expenditures: 17.2b Euro
Location: Imathia, Greece EU Cannabis has an option to acquire a 90-per-cent working interest in industrial hemp licences held by Cannatec Greece A.E. Cannatech currently holds three licences covering a total of 16 acres situated within the Greek prefecture of Imathia. The Highlights licences permit EU Cannabis to cultivate, manufacture, distribute and export industrial hemp and its many CBD-derived extracts. 16-acre land package for industrial hemp: EU Cannabis has received a preapproval support letter for a medical cannabis cultivation licence from the Hellenic Republic • Cultivation of Greece. This preapproval support letter grants the company permission to begin construction of its planned medical • Extraction cannabis cultivation facility in Imathia, Greece. The preapproval letter is comparable with the approval-to-build licence issued • Distribution by Health Canada to late-stage licensed producers (LPs) and ACMPR (Access to Cannabis for Medical Purposes Regulations) • Research and development candidates.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF PRODUCE & IMPORT CANNABIS IN ITALY ITALY
Ø Population: 60.6m ITALY Ø Healthcare Expenditures: 192.2b Euro Ø Estimated Cannabis Requirements 2018: 1,200,000 grams
• Front Runner for the 1st of 7 Licenses to be issued by the government for THC • 50.1% ownership in newly formed entity with Italian CBD factory. Strategic partners with a prevalent agriculture company in Occimiano. • Agricultural R&D collaborations with the University of East Piedmont, Science and Technology Department. • Greenhouse production of Cannabis for medical purposes in Occimiano region, available land 400 hectares • Focus on local sustainable practices and expertise in biomass energy production • Production of CBD for recreational purposes and THC for medical purposes • EU Certification of Production
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF MANUFACTURE, PROCESS AND EXTRACT CANNABIS MALTA
Ø Population: 460,297 MALTA Ø Health Care Expenditures: 820m Euro
Location: Malta Awarded a licence to manufacture finished-dose medical Cannabis by Malta Enterprise. Malta Enterprise is the country's official economic development agency and the government entity responsible for granting licences. Highlights International Cannabis’ Malta licence permits the Company to supply its Maltese operation with raw materials that • Licence to manufacture finished-dose will then undergo advanced post processing to create pure cannabis distillates, allowing for true pharmaceutical medical Cannabis manufacturing. Commercial production of distillates is integral for the company, as it advances the timeline for • Received a initial allocation of 2,750 square delivery of its full suite of products to European markets where such products are legal. metres of industrial space • Advanced postprocessing to create pure International Cannabis has received an initial allocation of 2,750 square metres of industrial space for its medical cannabis distillates, allowing for true Cannabis manufacturing operations. pharmaceutical manufacturing • Strategic located in close proximity to Europe
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF PROCESSED, EXTRACTION-READY HEMP INVENTORIES
International Cannabis has purchased 155 metric tonnes of processed industrial hemp from Eviana Health’s Serbian operations.
The companies estimate that by utilizing new extraction technology purchased by Eviana and integrated with their existing extraction equipment, the 155 metric tonnes of high-quality, organic cannabidiol (CBD) oils will be ready within 200 days.
International Cannabis also has entered into an exclusive supply agreement for the delivery of 400 metric tonnes of certified organic hemp from a licensed Croatian producer.
The immediate addition of already processed hemp which can be readily converted into high- quality, organic CBD oils allows the company to fulfill its growing pipeline of purchase orders in an expedited fashion.
International Cannabis plans to leverage its developing portfolio of brands as well as its robust distribution network of over 39,000 European pharmacies to maximize margins and profitability by marketing and selling CBD products derived from its Serbian and Croatian industrial stockpiles.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF PHARMACEUTICAL MANUFACTURING, COSMETICS AND BOTANICALS ALKALOID AD SKOPJE
MACEDONIA Ø Population: 2.074m
Location: Macedonia International Cannabis owns a 12% stake in Alkaloid AD Skopje, a Macedonian pharmaceutical manufacture. Alkaloid AD Skopje is equipped with eight decades of industry experience manufacturing drugs, cosmetic and Highlights chemical products, as well as processing botanical raw materials.
• Eight decades of industry experience Alkaloid operates two flagship profit centres: • Pharmaceuticals and Chemicals manufacturing drugs, cosmetic and • Cosmetics and Botanicals chemical products as well as processing botanical raw materials Alkaloid maintains a presence in Serbia, Montenegro, Kosovo, Albania, Bosnia and Herzegovina, Croatia, • 1,540 sq./m Institute for Development and Slovenia, Switzerland, Bulgaria, Turkey, Ukraine, the Russian Federation, and the USA. The Company has 1.430 Control of Quality employees in the country and 384 employees in subsidiaries and representative offices abroad.
Alkaloid recently unveiled its 8m Euro, Institute for Development and Control of Quality. The 1,540 square meters state-of-the-art facility is equipped with laboratory and revolutionary pilot-production equipment. The Institute is mandated with developing of new, modern types of generic drugs.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF CULTIVATE, PRODUCE, HOLD, SELL & EXPORT CANNABIS IN COLOMBIA CANNA COLOMBIA HOLDINGS INC.
Ø Population: 49.5m COLOMBIA Ø Health Care Expenditures: $22.6b Ø Estimated Medical Cannabis Allowance: 40,500,000 grams
Location: Colombia International Cannabis controls two separate licences to cultivate, produce, hold, sell and export cannabis and cannabis derivatives. The Company holds claim to 138 hectares of fertile, agricultural land and is in the process of Highlights establishing a EU-GMP certified API facility to process Cannabis distillates.
• 2 separate licences to cultivate, produce, hold, International Cannabis will cultivate THC cannabis outdoor and year-round with an infrastructure investment, sell and export cannabis and cannabis derivatives including 415,000 square feet of processing and clone and vegetation greenhouse facilities to support outdoor • 138 hectares of optimal agricultural land cannabis flower production. • Location of the Colombian Cannabis Centre of Excellence International Cannabis has entered into a joint venture with Estrella Verde, whereby the company will gain access • Import/Export Opportunity to over 300 registered genetic strains. The aforementioned strains have been registered with the ICA and are • Bolster International Supply Chain known to have passed ICA characterization-testing protocols. • 415,000 sq./ft of greenhouse for processing, clone and vegetation The company has passed the characterization protocols relating to its first 10 cannabis strains. International • 125 hectares of year round growth Cannabis plans to present these results to the ICA in the new year. International Cannabis expects to receive its final production quotas from the ICA in the first half of 2019.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF RECENT STRAIN ADDITIONS
ICC is committed to continual expansion of our world class genetics library on a world-wide basis:
Recent Strain Additions in 2019:
Mono Rojo Tambena Pajarita Caucanita #1 & #2 Terapi Cripaja Punto Rojo Mango Biche Purpura Pajarito Caucana OJ Black Maroc Liaerita Black Jesus Finola Nativa Medellin Gold Maracuja Our seed bank is poised to feed our global production chain with a world class selection of cannabis varietals.
Our extensive library covers some of the most sought after Indica, Sativa & Hybrid cannabis strains in the world. Our latest addition Medellin gold is a Cannabis Cup winning strain in Columbia.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF CULTIVATION, PRODUCTION AND EXTRACTION OF CANNABIS AND HEMP ARGENTINA
Ø Population: 44.69m ARGENTINA Ø Healthcare Expenditures: $43.4b
• Cultivation set to commence, August 2019 • First Federal licence in Argentina, expected approval in early 2019 • Plan to complete 150-hectare outdoor cultivation and a extraction facility • Domestic medical market for product • Establishment of GMP Certified API Manufacturing Facility in San Juan • Existing wine, juice and olive operations, providing US$1m in profit per annum • Existing supply agreements for CBD products from Canada to Argentinian Government • 819 hectares of existing developed agricultural land in San Juan province in Argentina • Recent construction of 120 megawatts of hydroelectricity production, new roads and a highly skilled labour pool, with a rich history of agricultural production and further processing capabilities
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF CULTIVATE, MANUFACTURE, SUPPLY, HOLD, IMPORT, EXPORT & TRANSPORT CANNABIS CANAFRICA HOLDINGS
Ø Population: 2.2331m KINGDOM OF LESOTHO Ø Health Care Expenditures: $275m
Location: Kingdom of Lesotho CanAfrica holds licences for medical Cannabis cultivation, manufacturing, distribution, transport, research and import/export in the Kingdom of Lesotho. Highlights Lesotho is a favourable jurisdiction for cannabis cultivation due to its rich soils, ideal climate, skilled • Licences for medical Cannabis cultivation, agricultural work force, low-cost labour and access to key infrastructure. manufacturing, distribution, transport, research and import/export in the Kingdom of Lesotho The Kingdom of Lesotho is an enclave of South Africa and will act as a cultivation and production hub for International Cannabis' 2,800 South African pharmacies. Both South Africa and Lesotho are members of the • 300 days of sunshine annually South African Customs Union (SACU), which aims to maintain the free interchange of goods between • Lesotho was the first African nation to legalize member countries. medical cannabis in 2017 • Ideal climate for low-cost greenhouse cannabis production
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF CONSUMER PRODUCTS, STRATEGIC PARTNERSHIPS, MANAGEMENT, EDUCATIONAL AND TRAINING RESOURCES ARICANNABIS
Ø Population: 56.72m SOUTH AFRICA Ø Health Care Expenditures: $8.8b
Location: South Africa Aricannabis works on an exclusive basis with NuCare Health (“NuCare”) to provide Cannabis products to over 2,800 independent and corporate pharmacies across South Africa. NuCare also provides their medical Highlights partners with the following:
• Provide Cannabis products to over 2,800 • Access to innovative consumer products; independent and corporate pharmacies across • Strategic partnerships with key suppliers; South Africa • Management of channel pressure; and • September 18, 2018 South Africa's Constitutional • Educational and training resources. Court unanimously voted to legalize adult cannabis consumption, as well as the cultivation of The alignment of the International Cannabis Corp.’s existing African cultivation capabilities and distribution cannabis for private consumption channels, complemented by these new established marketing and distribution channels will augment the Company’s African seed-to-sale objectives.
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF MEDICAL CANNABIS APPLICANT FOR PRODUCTION AUSTRALIA
Ø Population: 25.2m AUSTRALIA Ø Healthcare Expenditures: $113b US
• Late stage medical Cannabis applicant coupled with a Northern Territory sponsorship • Securing land parcel in Darwin, Australia, an ideal climate for production • Medicare is Australia’s universal healthcare system, which is the primary scheme that subsidizes specific indications • Streamlined prescription process • Widespread acceptance of Cannabinoid therapeutics by Australia’s medical community
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF Flagship Strategic Investment - Auxly
Auxly Cannabis Group Inc. completed a $5 million strategic investment into International Cannabis by way of convertible debentures. The marriage of International Cannabis and Auxly adds a significant amount of option value to both international platforms of both Companies, effectively expanding international footprint to 22 countries across 5 continents.
Auxly Auxly + WRLD Auxly + WRLD + Cosmos Holdings
North America North America Europe North America Asia Europe • Canada • Canada • Denmark • Canada • United Arab Emirates • Denmark • Poland • Singapore • Slovenia South America • Switzerland South America • Lebanon • Germany South America • Germany • Jordan • United Kingdom • Uruguay • • Uruguay Uruguay • Macedonia • Ireland • • Columbia Columbia • Bulgaria Oceania • Italy • Argentina • Argentina • Greece • Australia • France • Italy • Macedonia Africa • Portugal Africa • Sweden • Lesotho • Malta • Lesotho • Poland • South Africa • United Kingdom • South Africa • Netherlands • Greece • Switzerland Oceania • Bulgaria • Australia • Portugal • Malta
intlcannabiscorp.com CSE:WRLD.U FWB:8K51 OTC:WLDCF Our Team
David Shpilt CEO Mr. David Shpilt boasts over four years of cannabis cultivation experience under Health Canada’s ACMPR (formerly MMPR) framework. David has worked directly with numerous master growers at commercially licensed producers, assisting to improve cultivation methodologies, as well as standardizing the cannabis cultivation to pharmaceutical standards. David is equipped with a robust network of international contacts within the cannabis industry and boasts a deep understanding of patient education and services.
Throughout his career, David has succeeded in congregating Physicians together with Complimentary and Alternative Practitioners within interdisciplinary settings, and most recently has stepped into functional medicine and clinical treatment offerings adjunctive to traditional frontline protocols. Mutually beneficial professional relationships with Physicians, coupled with a strong understanding of patient education and patient services, has made David a natural fit within the medical cannabis industry.
Eugene Beukman Director Mr. Beukman is the corporate counsel of the Pender group of companies, a position he has held since January, 1994. He graduated from Rand University of Johannesburg, South Africa, with a bachelor of law degree and a bachelor of law honours postgraduate degree in 1987. After practising as a lawyer, Mr. Beukman was employed as a legal adviser to the BHP Billiton group of companies. He has over 30 years of experience in the acquisition of assets and joint ventures. He is an advocate of the High Court of South Africa, and serves as chief executive officer and director on a number of TSX Venture Exchange-listed and Canadian Securities Exchange-listed companies. Our Team
Peter Nguyen CFO Mr. Nguyen is a chartered accountant and holds a degree from the University of British Columbia. He has held senior financial positions for both public and private companies where he provided assurance, corporate finance, tax and business advisory services.
Michael Martinz President & Director Mr. Michael Martinz has been the President of Kaneh Bosm BioTechnology Inc. (formerly Anexco Resources Ltd) since April 2014. Mr. Martinz is an innovative entrepreneur with experience spanning various sectors including resource, agriculture/horticulture, high-tech, manufacturing and most recently, alternative energy. His business experience encompasses Canada, the United States, China, Hong Kong, Africa and Japan. He has been particularly successful in identifying and capitalizing on high margin niche market opportunities.
Brendan Purdy Director Mr. Purdy is a practicing securities lawyer focused on technology, Cannabis and resource issuers. In his private practice, he has developed domestic and international experience with respect to public companies, reverse takeovers, mergers and acquisitions (M&A), and many facets fundamental to the Canadian capital markets. Prior to receiving his J.D. from the common-law section at the University of Ottawa, Mr. Purdy completed a bachelor of management and organizational studies degree from the University of Western Ontario, majoring in finance and administration. Mr. Purdy serves as a director of a number of CSE- and TSX Venture Exchange-listed companies. Suite 810 – 789 West Pender Street Vancouver, BC V6C 1H2 p: 604 687-2038 e: [email protected] intlcannabiscorp.com
CSE:WRLD.U FWB:8K51 OTC:WLDCF